Opendata, web and dolomites

DRIVE SIGNED

Development of Robust and Innovative Vaccine Effectiveness

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "DRIVE" data sheet

The following table provides information about the project.

Coordinator
FUNDACION PARA EL FOMENTO DE LA INVESTIGACION SANITARIA Y BIOMEDICA DE LA COMUNITAT VALENCIANA 

Organization address
address: CALLE MICER MASCO 31
city: VALENCIA
postcode: 46010
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.drive-eu.org
 Total cost 9˙999˙937 €
 EC max contribution 8˙999˙812 € (90%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2016-09-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2017
 Duration (year-month-day) from 2017-07-01   to  2022-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACION PARA EL FOMENTO DE LA INVESTIGACION SANITARIA Y BIOMEDICA DE LA COMUNITAT VALENCIANA ES (VALENCIA) coordinator 5˙684˙187.00
2    P95 CVBA BE (LEUVEN) participant 478˙062.00
3    SYNAPSE RESEARCH MANAGEMENT PARTNERS SL ES (MADRID) participant 393˙750.00
4    ISTITUTO SUPERIORE DI SANITA IT (ROMA) participant 382˙500.00
5    UNIVERSITA DEGLI STUDI DI FIRENZE IT (Florence) participant 350˙812.00
6    TERVEYDEN JA HYVINVOINNIN LAITOS FI (HELSINKI) participant 349˙250.00
7    ASSOCIATION INTERNATIONALE DE STANDARDISATION BIOLOGIQUE POUR L'EUROPE (IABS-EU) FR (LYON) participant 323˙437.00
8    UNIVERSITE LYON 1 CLAUDE BERNARD FR (VILLEURBANNE CEDEX) participant 315˙250.00
9    INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT FR (MARSEILLE) participant 303˙687.00
10    UNIVERSITY OF SURREY UK (GUILDFORD) participant 257˙375.00
11    CONFEDERATION OF MENINGITIS ORGANISATIONS LTD UK (BRISTOL) participant 161˙500.00
12    ABBOTT BIOLOGICALS BV NL (WEESP) participant 0.00
13    GLAXOSMITHKLINE BIOLOGICALS SA BE (RIXENSART) participant 0.00
14    SANOFI PASTEUR SA FR (LYON) participant 0.00
15    SEQIRUS UK LIMITED UK (MAIDENHEAD) participant 0.00

Map

 Project objective

Influenza is a major public health problem. In a conservative estimate, influenza infects annually 60 of the 500 million inhabitants of the EU. Vaccines are the cornerstone for preventing influenza and its consequences. Current influenza vaccines have a moderate variable effect, given the mismatch between vaccine and circulating strains, waning immunity and interference from previous vaccination, among others.

The single most important challenge in achieving VE studies for the various influenza vaccines put every year on the European market is the ability of the different stakeholders to work in collaboration.

To enable a sustainable network of influenza vaccine VE studies, the Development of Robust and Innovative Vaccines Effectiveness (DRIVE) main goal will be the development of a governance model between public and private entities. This model will ensure scientific independence in the studies and full transparency, allowing different stakeholders to fulfill their needs taking into account their respective obligations and statutes.

A second challenge will be to reach the capacity to perform vaccine brand- specific effectiveness studies, which is agile enough to deliver the needed outputs in timely manner, and robust enough to provide results by different age and risk groups and flexible enough to utilize novel tools while at the same time aims to be sustainable.

Combining these outputs, DRIVE will establish a sustainable platform for joint influenza vaccine effectiveness evaluation which will have a positive impact on European citizens public health.

 Deliverables

List of deliverables.
Governance Standard Operating Procedures (SOP) Documents, reports 2020-01-14 14:31:02
Web-based survey amongst layer 1 stakeholders Documents, reports 2019-11-20 12:24:09
Report on the Governance SOP implementation Documents, reports 2019-11-20 12:24:09
Report on synergies identified and collaborations developed with other initiatives Documents, reports 2019-11-20 12:24:09
Updated and developed protocol for type- and brand- specific IVES Documents, reports 2019-11-20 12:24:09
Report on feasible novel and innovative approaches for measuring influenza VE Documents, reports 2019-11-20 12:24:09
Report on the collected feed-back from “layer 1” […] Documents, reports 2019-11-20 12:24:09
First seasonal final report of conducted studies Documents, reports 2019-11-20 12:24:09
Updated protocol for type- and brand- specific influenza vaccine effectiveness studies (population-based database studies) Documents, reports 2019-11-20 12:24:09
Communication report of the study milestones arising from WP7 for the use of “layer 1” stakeholders Documents, reports 2019-11-20 12:24:09
Annual tender for influenza vaccine effectiveness study conduct Documents, reports 2019-11-20 12:24:09
Methodology guidelines for concerted analysis of data and control of confounding factors Documents, reports 2019-11-20 12:24:08
Points to consider document on the interpretation of VE results Documents, reports 2019-11-20 12:24:08
Project Handbook Documents, reports 2019-11-20 12:24:08
Generic SAP Documents, reports 2019-11-20 12:24:08
IT infrastructure to receive and analyse the data Websites, patent fillings, videos etc. 2019-11-20 12:24:08
Report on the sources for usage of specific influenza vaccine brands and accessibility Documents, reports 2019-11-20 12:24:08
Report with the definition of the ethics policies handbooks collection Documents, reports 2019-11-20 12:24:08
Generic DMP Documents, reports 2019-11-20 12:24:08
Standard Operating Procedures (SOPs) and templates Documents, reports 2019-11-20 12:24:08
Multi Stake-holder Research Agenda Documents, reports 2019-11-20 12:24:08
SWOT analysis plan and list of quality criteria Documents, reports 2019-11-20 12:24:08
Report on the comparison of adapted local protocols and Ethical Committee evaluation in each study site Documents, reports 2019-11-20 12:24:08
Report templates Documents, reports 2019-11-20 12:24:08
Communication of a detailed stakeholder map for the DRIVE project Documents, reports 2019-11-20 12:24:08
Report on the brand availability and usage of specific influenza vaccine brands Documents, reports 2019-11-20 12:24:08
Development of the communications plan Documents, reports 2019-11-20 12:24:08
Guideline for the identification of vaccine status and vaccine used in study participants Documents, reports 2019-11-20 12:24:09
Report of the results of a systematic analysis on existing initiatives, tools, and/or study protocols for determining IVE […] Documents, reports 2019-11-20 12:24:09
Electronic study support application Websites, patent fillings, videos etc. 2019-11-20 12:24:09
Evaluation reports of how the vaccine effectiveness results could fulfil the new regulatory requirements Documents, reports 2019-11-20 12:24:09
Written report on quality and feasibility evaluation Documents, reports 2019-11-20 12:24:09
Agreement on communications governance model Documents, reports 2019-11-20 12:24:09
Tailored, timely seasonal summaries of VE results for different stakeholder/clients in layer 1 and 2 Documents, reports 2019-11-20 12:24:09
Periodical back-to-back Forum of key stakeholders […] Documents, reports 2019-11-20 12:24:09

Take a look to the deliverables list in detail:  detailed list of DRIVE deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DRIVE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DRIVE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

AB-DiRecT (2019)

Antibiotic Distribution and Recovery in Tissue

Read More  

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More  

RespiriTB (2019)

Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors

Read More